Beta Bionics (Nasdaq:BBNX) shares remained unmoved after hours today on first-quarter results that topped the consensus sales forecast.
Following its first-quarter performance, Beta Bionics increased its full-year guidance. After previously projecting between $80 million and $85 million in revenue, it now expects between $82 million and $87 million.
The Irvine, California-based automated insulin delivery technology developer reported losses of $18.6 million. That equals 93¢ per share on sales of $17.6 million for the three months ended March 31, 2025.
Beta Bionics, maker of the iLet bionic pancreas, recorded a more than $9 million bottom-line slide on a sales uptick of 36.4%.
Losses per share landed 42¢ behind expectations on Wall Street. Sales topped estimates, though, as experts forecast $16.15 million in revenue.
Beta Bionics’ growth was driven by the continued rollout of the iLet system. The company reported 19,151 users in its installed customer base, a massive rise from 4,901 in the same period a year ago. It also reports 3,853 new patient starts, up 48% from 2,597 in 2024. Nearly a quarter of the new starts (71%) came from multiple daily injections (MDI).
Highlights in the quarter included the completion of a $234.6 million IPO in January, taking it public. The company also announced pharmacy benefit victories, including its addition to the Prime Therapeutics national commercial formulary. Beta Bionics also initiated enrollment in March for a trial evaluating glucagon pharmacokinetic-pharmacodynamic bridging in Canada. This trial aims to enable the company to bridge previous bihormonal data.
